YorkBridge Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

YorkBridge Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-669	Closed	-$57K	–	225
2019 Q2	$57K	Buy	669 +53	+9%	+$4.53K	0.03%	355
2019 Q1	$55K	Buy	616 +10	+2%	+$927	0.03%	351
2018 Q4	$52K	Buy	606 +263	+77%	+$25K	0.03%	329
2018 Q3	$34K	Buy	343 +22	+7%	+$2.2K	0.02%	399
2018 Q2	$30K	Buy	+321	New	+$28.1K	0.01%	425

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

YorkBridge Wealth Partners's BMRN Position: Q3 2019 in Review

YorkBridge Wealth Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 669 shares — an estimated $57K sold.

YorkBridge Wealth Partners first reported a position in BMRN in Q2 2018 and held it in 5 quarters. The position peaked at $57K in Q2 2019. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

YorkBridge Wealth Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
YorkBridge Wealth Partners sold 669 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $57K.
YorkBridge Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 5 quarters.
YorkBridge Wealth Partners's BioMarin Pharmaceuticals position peaked at $57K in Q2 2019.
436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2019, filed 21 Oct 2019.